Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMRIH0S)

Drug Name

SAR113244 Drug Info

Synonyms

LPA-1/LPA-3

Indication

Disease Entry	ICD 11	Status	REF
Systemic lupus erythematosus	4A40.0	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Preclinical Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting C-X-C chemokine receptor type 5 (CXCR5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PF-06835375	DMNIYPS	Immune thrombocytopenic purpura	3B64.13	Phase 2	[3]
JT08	DM8OAZ6	Solid tumour/cancer	2A00-2F9Z	Preclinical	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
C-X-C chemokine receptor type 5 (CXCR5)	TTIW59R	CXCR5_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT02321709) Multiple Ascending Dose Study To Assess The Safety Profile Of SAR113244 Versus Placebo In Lupus Male And Female Patients. U.S. National Institutes of Health.
2	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
3	ClinicalTrials.gov (NCT05070845) AN INTERVENTIONAL PHASE 2, OPEN-LABEL, MULTI-CENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF PF-06835375 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE PRIMARY IMMUNE THROMBOCYTOPENIA. U.S.National Institutes of Health.
4	Clinical pipeline report, company report or official report of Jyant Technologies.